Drugs Made In America Acquisition Corp

Drugs Made In America Acquisition Corp（DMAA）の株式分析

$10.750

0.000 (0.00%)終値時点

Loading chart…
High
10.755
Open
10.740
VWAP
10.75
Vol
4.13K
Mkt Cap
—
Low
10.740
Amount
44.39K
EV/EBITDA, TTM
0.00

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.

dmaacorp.com

AI analysis of Drugs Made In America Acquisition Corp (DMAA)

hold

Currently, DMAA is not a strong buy due to its high P/E ratio of 55.63 and a low current ratio of 0.02, indicating potential liquidity issues. The RSI is at 61.24, suggesting it is nearing overbought territory, which may limit upside potential in the short term.

バリュエーション指標

The current forward P/E ratio for Drugs Made In America Acquisition Corp (DMAA) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
割高
0.00
割安
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
割高
0.00
割安
0.00

Forward P/S

Fair
5Y Average P/S
0.11
Current P/S
0.00
割高
1.18
割安
-0.96

Alphio AI Price Scenarios for DMAA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%DMAA

$10.91

シナリオ価格

B

Base

Base · 50%DMAA

$9.82

シナリオ価格

B

Bear

Bear · 25%DMAA

$9.57

シナリオ価格

Whales holding DMAA

A

Aristeia Capital, LLC

+ HoldingDMAA

+4.07%

3M Return

P

Polar Asset Management Partners Inc.

+ HoldingDMAA

+0.48%

3M Return

W

Wolverine Asset Management, LLC

+ HoldingDMAA

-9.74%

3M Return

DMAA FAQ — answered by Alphio AI

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.

Currently, DMAA is not a strong buy due to its high P/E ratio of 55.63 and a low current ratio of 0.02, indicating potential liquidity issues. The RSI is at 61.24, suggesting it is nearing overbought territory, which may limit upside potential in the short term.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める